Contributions from surgeons to clinical trials and research on the management of soft tissue sarcoma

1998 ◽  
Vol 5 (5) ◽  
pp. 437-441 ◽  
Author(s):  
Peter J. Allen ◽  
Alexander Stojadinovic ◽  
Craig D. Shriver ◽  
David P. Jaques
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma

scholarly journals Access to clinical trials for soft tissue sarcoma patients in Western and Eastern Europe

2019 ◽  
Vol 30 ◽  
pp. v693
Author(s):  
V. Ostafiichuk ◽  
S.I. Korovin ◽  
M.N. Kukushkina
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Eastern Europe

scholarly journals Application of a widely-used tropical anti-worm agent, mebendazole, in modern oncology

2017 ◽  
Vol 16 (10) ◽  
pp. 2555-2562 ◽  
Author(s):  
Dušica J Popović ◽  
Mihalj Poša ◽  
Kosta J Popović ◽  
Jovanka Kolarović ◽  
Jovan K. Popović ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Glioblastoma Multiforme ◽  
Cell Growth ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Acute Myeloid Leukaemia ◽  
Preclinical Studies ◽  
Cancer Cell Growth ◽  
Tropical Areas ◽  
Acute Myeloid

Although clinical trials have not been completed, it has already been confirmed that mebendazole, a well-known anti-parasitic drug widely used in the tropical areas, inhibits cancer cell growth. Preclinical studies show that mebendazole notably impedes the growth of malignant and metastatic tumors such as osteosarcoma and soft tissue sarcoma, melanoma, carcinoma (lung, colorectal, breast, ovarian, hepatocellular and adrenocortical), acute myeloid leukaemia, glioblastoma multiforme and  meduloblastoma. Mebendazole can induce the depolymerization of microtubules in neoplasms and newly formed vasculature, stopping tumor growth and neoangiogenesis, along with other proposed mechanisms of action.Keywords: Anthelmintic, Mebendazole, Cancer treatment, Antimicrotubullar effect, Antineoangiogenesis

scholarly journals Update on Systemic Therapy for Advanced Soft-Tissue Sarcoma

2020 ◽  
Vol 27 (11) ◽  
pp. 25-33 ◽  
Author(s):  
A. Smrke ◽  
Y. Wang ◽  
C. Simmons
Keyword(s):  
Overall Survival ◽  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Systemic Therapy ◽  
English Language ◽  
Standard Of Care ◽  
Current Evidence ◽  
First Line ◽  
First Line Therapy

Background: Soft-tissue sarcoma (sts) represents a rare group of mesenchymal neoplasms comprising more than 50 heterogeneous subtypes. Great efforts have been made to increase the understanding of the treatment of advanced sts (unresectable or metastatic disease). We set out to determine whether outcomes for patients with advanced sts have improved over time and to assess the current evidence for systemic therapy. Methods: In a scoping review, we evaluated the contemporary evidence for systemic treatment of advanced sts in adults (>18 years of age). Phase i, ii, and iii studies of systemic therapy for advanced sts published in the English language were included. After abstract and full-text review of seventy-seven studies, sixty-two trials met the inclusion criteria. Results: The number of clinical trials conducted and published in advanced sts has increased over the last 30 years. Although median overall survival has increased, attempts at improving first-line therapy through dose intensification, doublet chemotherapy, or alternative backbones have not been successful. The optimal therapy beyond anthracyclines remains a challenge, especially given the heterogeneity that grouping multiple sts subtypes within clinical trials creates. However, increasing numbers of agents are being studied, and several studies had shown isolated benefit in progression-free or overall survival. Summary: First-line systemic therapy with an anthracycline remains the standard of care for advanced sts. However, choice of subsequent therapy beyond anthracyclines remains challenging. Novel systemic therapies, use of molecular diagnostics to direct therapy, subtype-specific trials, and learnings from real-world retrospective data are all important for improving outcomes in patients with advanced sts.

scholarly journals Time lapse analysis of tumor response in patients with soft tissue sarcoma treated with trabectedin: A pooled analysis of two phase II clinical trials

2020 ◽  
Vol 9 (11) ◽  
pp. 3656-3667
Author(s):  
Makoto Endo ◽  
Shunji Takahashi ◽  
Nobuhito Araki ◽  
Hideshi Sugiura ◽  
Takafumi Ueda ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Phase Ii ◽  
Tumor Response ◽  
Time Lapse ◽  
Pooled Analysis ◽  
Two Phase ◽  
Phase Ii Clinical Trials
Sign in / Sign up

Export Citation Format

Share Document